|
|
|
|
|
|
|
|
open access (technical)
Introduction
Lynch syndrome
is estimated to cause 2–4 % of ovarian cancer. Recognition of these
cases is challenging, and many of the 9,000 ovarian cancers annually
estimated to develop as part of Lynch syndrome probably escape
detection. Whereas sporadic ovarian cancer and hereditary cancer caused
by BRCA1 and BRCA2
gene mutations develop at a mean age of 65–70 years, typically show
serous histopathology and present at advanced tumor stages [1, 2],
ovarian cancer linked to Lynch syndrome typically develops at a mean
age of 45 years as early-stage tumors of the endometrioid and clear cell
histologic subtypes [2–7]. Lynch syndrome is caused by germline mutations in the mismatch-repair (MMR) genes MLH1, MSH2, MSH6 and PMS2.
Carriers of disease-predisposing mutations are estimated to be at
7–12 % life-time risk for ovarian cancer, at 50–80 % risk for colorectal
cancer and at 40–60 % risk for endometrial cancer [5, 8, 9].
Recognition of ovarian cancers linked to Lynch syndrome tumors is
important since family members at risk can be offered surveillance
and/or prophylactic measures that reduce morbidity and mortality, not
least from the more commonly occurring colorectal cancers.
In
ovarian cancer, the different histopathologic subtypes have been
suggested to constitute separate disease entities with differences
related to biological features, treatment response and prognosis [10, 11].......#ovariancancers
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.